Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor - PubMed (original) (raw)
Comparative Study
. 2002 Nov 15;100(10):3825-7.
doi: 10.1182/blood-2002-04-1197. Epub 2002 Jul 5.
Affiliations
- PMID: 12393440
- DOI: 10.1182/blood-2002-04-1197
Free article
Comparative Study
Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor
Stella M Davies et al. Blood. 2002.
Free article
Abstract
One of the functions of HLA class I alleles is interaction with natural killer (NK) cells. Receptors termed killer immunoglobulin-like receptors (KIRs) on NK cells recognize groups of HLA class I alleles, and interaction between receptor and class I allele inhibits reactivity of the NK cell. Failure to recognize the appropriate KIR ligand on a mismatched cell can trigger NK cell elimination of that target cell. Recent analysis of haploidentical hematopoietic transplantations has shown a reduction of graft failure, graft-versus-host disease, and relapse in those with KIR ligand incompatibility in the graft-versus-host direction. In this study we analyzed the effect of KIR ligand incompatibility on outcomes of unrelated donor bone marrow transplantations. The data show no advantage for KIR ligand incompatibility in this clinical setting as assessed by HLA-Bw4 and HLA-C alleles. It is possible that there will be a benefit of NK cell alloreactivity if strategies of haploidentical transplantation are used: high stem cell doses, extensive T-cell depletion, and no postgrafting immune suppression.
Similar articles
- Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors.
Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, Maccario R, Bonetti F, Wojnar J, Martinetti M, Frassoni F, Giorgiani G, Bacigalupo A, Holowiecki J. Giebel S, et al. Blood. 2003 Aug 1;102(3):814-9. doi: 10.1182/blood-2003-01-0091. Epub 2003 Apr 10. Blood. 2003. PMID: 12689936 Clinical Trial. - Killer-cell immunoglobulin-like receptor ligand compatibility in the outcome of Finnish unrelated donor hematopoietic stem cell transplantation.
Sivula J, Volin L, Porkka K, Vettenranta K, Itälä M, Partanen J, Turpeinen H. Sivula J, et al. Transpl Immunol. 2007 Jul;18(1):62-6. doi: 10.1016/j.trim.2007.03.006. Epub 2007 Apr 19. Transpl Immunol. 2007. PMID: 17584604 - Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.
Verheyden S, Ferrone S, Mulder A, Claas FH, Schots R, De Moerloose B, Benoit Y, Demanet C. Verheyden S, et al. Cancer Immunol Immunother. 2009 Jun;58(6):855-65. doi: 10.1007/s00262-008-0601-7. Epub 2008 Oct 8. Cancer Immunol Immunother. 2009. PMID: 18841361 Free PMC article. - Role of KIRs and KIR ligands in hematopoietic transplantation.
Velardi A. Velardi A. Curr Opin Immunol. 2008 Oct;20(5):581-7. doi: 10.1016/j.coi.2008.07.004. Epub 2008 Aug 23. Curr Opin Immunol. 2008. PMID: 18675345 Review. - [KIRs on human NK cells and in relation with HLA class I antigen--review].
Dou LP, Da WM. Dou LP, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Jun;14(3):627-30. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006. PMID: 16800958 Review. Chinese.
Cited by
- Children's Oncology Group's 2023 blueprint for research: Cellular therapy and stem cell transplantation.
Kitko CL, Bollard CM, Cairo MS, Chewning J, Fry TJ, Pulsipher MA, Shenoy S, Wall DA, Levine JE. Kitko CL, et al. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30577. doi: 10.1002/pbc.30577. Epub 2023 Jul 21. Pediatr Blood Cancer. 2023. PMID: 37480158 Free PMC article. - Allogeneic natural killer cell therapy.
Berrien-Elliott MM, Jacobs MT, Fehniger TA. Berrien-Elliott MM, et al. Blood. 2023 Feb 23;141(8):856-868. doi: 10.1182/blood.2022016200. Blood. 2023. PMID: 36416736 Free PMC article. Review. - Natural killer cells in antitumour adoptive cell immunotherapy.
Laskowski TJ, Biederstädt A, Rezvani K. Laskowski TJ, et al. Nat Rev Cancer. 2022 Oct;22(10):557-575. doi: 10.1038/s41568-022-00491-0. Epub 2022 Jul 25. Nat Rev Cancer. 2022. PMID: 35879429 Free PMC article. Review. - The Interaction of HLA-C1/KIR2DL2/L3 Promoted KIR2DL2/L3 Single-Positive/NKG2C-Positive Natural Killer Cell Reconstitution, Raising the Incidence of aGVHD after Hematopoietic Stem Cell Transplantation.
Zuo W, Yu XX, Liu XF, Chang YJ, Wang Y, Zhang XH, Xu LP, Liu KY, Zhao XS, Huang XJ, Zhao XY. Zuo W, et al. Front Immunol. 2022 Apr 29;13:814334. doi: 10.3389/fimmu.2022.814334. eCollection 2022. Front Immunol. 2022. PMID: 35572602 Free PMC article. - Natural Killer Cell-Mediated Cellular Therapy of Hematological Malignancies.
Sahin U, Beksac M. Sahin U, et al. Clin Hematol Int. 2019 Sep 1;1(3):134-141. doi: 10.2991/chi.d.190623.001. eCollection 2019 Sep. Clin Hematol Int. 2019. PMID: 34595423 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials